{
    "clinical_study": {
        "@rank": "18545", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Evaluate insulin resistance in thin and obese hyperandrogenic women with\n      polycystic ovarian disease or hyperandrogenism insulin resistance acanthosis nigricans\n      syndrome and in thin and obese controls, using an estimation of tissue sensitivity to\n      insulin.\n\n      II.  Evaluate the effect of androgen suppression with leuprolide acetate and spironolactone\n      on insulin secretion and resistance."
        }, 
        "brief_title": "Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome", 
        "completion_date": "January 1996", 
        "condition": [
            "Acanthosis Nigricans", 
            "Polycystic Ovary Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acanthosis Nigricans", 
                "Insulin Resistance", 
                "Polycystic Ovary Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Participants are treated with subcutaneous leuprolide acetate followed by\n      oral spironolactone.  Each treatment is administered daily for 6 weeks, with a 6-week\n      washout between drugs.\n\n      Patients and controls are alternately assigned to begin treatment with leuprolide acetate or\n      spironolactone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Polycystic ovarian disease Oligomenorrhea or amenorrhea\n        Hirsutism Hyperandrogenism Hyperandrogenism insulin resistance acanthosis nigricans\n        syndrome Hyperandrogenism Oligomenorrhea or amenorrhea Insulin resistance Acanthosis\n        nigricans Hematocrit at least 30% Women with normal menstrual cycles not using oral\n        contraception entered as controls"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004311", 
            "org_study_id": "199/11816", 
            "secondary_id": "BCM-467"
        }, 
        "intervention": [
            {
                "intervention_name": "leuprolide acetate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "spironolactone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Spironolactone", 
                "Leuprolide"
            ]
        }, 
        "keyword": [
            "acanthosis nigricans", 
            "dermatologic disorders", 
            "endocrine disorders", 
            "polycystic ovarian syndrome", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Baylor College of Medicine", 
            "last_name": "Karen E. Elkind-Hirsch", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004311"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Baylor College of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "July 1989", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2000"
    }, 
    "geocoordinates": {}
}